Baxter International vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deerfield IL hospital medical technology (NYSE: BAX) at $10.636B 2024 revenue; Vantive kidney care sold to Carlyle $3.8B (Jan 2025), new CEO Andrew Hider (Sep 2025) competing with ICU Medical for IV solutions and infusion systems.
About
Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Baxter International vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.